Advertisement

Reactions Weekly

, Volume 1778, Issue 1, pp 79–79 | Cite as

Avitinib/erlotinib/osimertinib

Acute interstitial lung disease and development of resistance: case report
Case report
  • 23 Downloads

Reference

  1. Wang H, et al. Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. OncoTargets and Therapy 12: 5545-5549, Jul 2019. Available from: URL: http://doi.org/10.2147/OTT.S204689 - China

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations